-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Passage Bio, Maintains $6 Price Target

Benzinga·06/24/2025 12:19:46
Listen to the news
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and maintains $6 price target.